(thirdQuint)Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer.

 Sipuleucel-T will be administered as standard of care.

 Oral Indoximod/placebo will be self-administered twice daily for 6 months starting after the last infusion of sipuleucel-T.

 Patients will be treated for a minimum of 12 weeks of Indoximod/placebo before disease progression can be declared and Indoximod/placebo will not be discontinued for increasing prostate specific antigen (PSA) in the absence of symptomatic clinical progression.

.

 Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer@highlight

This is a randomized, double blind, multi-institutional phase II therapeutic study of Indoximod or placebo after the completion of standard of care sipuleucel-T (Provenge(R)) in men with asymptomatic or minimally symptomatic metastatic prostate cancer that is castration resistant (hormone refractory).

 Patients are randomized to receive either twice daily oral Indoximod or placebo for 6 months beginning the day after the third and final sipuleucel-T infusion.

